Pacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.22, $0.05 worse than the analyst estimate of $0.27. Revenue for the quarter came in at $69.3 million versus the consensus estimate of $68.4 million.

“We finished 2015 with a solid performance in spite of the challenges we faced this past year,” said Dave Stack, chief executive officer and chairman of Pacira. “In 2016, we look forward to refocusing our efforts on developing and supporting the untapped market opportunities for EXPAREL and DepoFoam®, starting with the official oral surgery launch, advancement of robust clinical programs in nerve block and orthopedic procedures as well as patient and healthcare provider outreach.”

Pacira expects the following operating expenses for 2016:

• Non-GAAP research and development (R&D) expense of $60 million to $70 million.
• Non-GAAP selling, general and administrative (SG&A) expense of $125 million to $135 million.
• Stock-based compensation expense of $35 million to $40 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.